Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC fully-diluted shares @4/28/23=102.8M—an increase of 1.7M since 12/31/22 (#msg-171323876):

• 84.0M basic shares on the 3/31/23 balance sheet (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000147929023000072/rvnc-20230331.htm#ia1ea4fa82c274a04af0ffacf37952862_16 );

• 4.5M stock options (ibid p.36);

• 5.4M shares of unvested restricted stock and RSU/PSUs (ibid); and

• 8.9M shares deriving from the convertible debt issued in Feb 2020.

Note: No shares have been sold under the 2022 ATM facility (as of 3/31/23).